Visgenx Appoints William Pedranti as Chief Executive Officer

The Company is developing VGX-0111, a gene therapy candidate for Dry Age-related Macular Degeneration (AMD), an aging related disorder and a leadi...

Related Keywords

Arthur Becker ,William Pedranti ,Martin Emanuele ,Prnewswire Visgenx Inc ,Company Board Of Directors ,Visgenx Inc ,Georgetown University Law Center ,University Of Southern California ,Business Administration ,Dry Age Related Macular Degeneration ,Chief Executive ,Chief Science ,Science Ventures ,Southern California ,Georgetown University Law ,Age Related Macular Degeneration ,Private Securities Litigation Reform Act ,